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Abstract: A 48-hour course of intravenous unfractionated heparin (UFH) is the standard of treatment in conjunction with 
fibrin-specific thrombolysis in ST-elevation myocardial infarction (STEMI). In recent trials, the efficacy and safety of in-
hospital administration of subcutaneous low-molecular-weight heparins (LMWH), previously proven effective in non-ST-
elevation acute coronary syndromes, have been investigated in the setting of STEMI. The aim of this review was to evalu-
ate the available evidence supporting the use of LMWH in STEMI. 
Overall, about 27,000 patients treated with various thrombolytic regimens, were included in 12 open-label randomized 
clinical trials, where dalteparin, reviparin or enoxaparin were administered. While acknowledging the wide variability in 
study dimensions, designs and end-points, a higher efficacy of LMWH was observed overall as compared to placebo, and 
also to UFH (mainly as regards the occurrence of reinfarction). As regards safety, bleedings were more frequent than pla-
cebo and comparable to UFH in LMWH groups, with the exception of the pre-hospital ASSENT-3 PLUS trial, where in 
elderly patients, enoxaparin had an incidence of intracranial hemorrhage twice higher than UFH. In a recent double-blind, 
randomized, mega-trial including over 20,000 patients, the superior efficacy on in-hospital and 30-day adverse cardiac 
events (namely reinfarction), and comparable safety on intracranial bleedings, of enoxaparin compared to UFH, was 
shown. 
In conclusion, in-hospital subcutaneous administration of dalteparin, reviparin and enoxaparin, as an adjunct to various 
thrombolytics in STEMI, appears feasible and at least as effective and safe as 48-hour intravenous treatment with UFH. In 
accordance with the available strongest evidence, an initial intravenous bolus of enoxaparin followed by twice daily sub-
cutaneous administration for about 1 week should be the preferred regimen, and should be strongly considered instead of 
intravenous UFH. Along with its easiness of use, not requiring laboratory monitoring, subcutaneous administration of 
LMWH following STEMI treated with thrombolysis allows extended antithrombotic treatment, while permitting early 
mobilization (and rehabilitation) of patients. 
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INTRODUCTION 
Rapid and complete dissolution of the occlusive coronary 
thrombus is the objective of thrombolytic treatment in acute 
ST-elevation myocardial infarction (STEMI). Upon clot lysis 
however, thrombin is exposed and further clot formation is 
promoted [1]. In addition, plasmin mediated activation of the 
coagulation system has been shown to be important, as 
judged by plasma increases of markers of prothrombin acti-
vation and thrombin activity (Eisenberg et al, JACC 2002). 
Thrombin induces platelet activation, fibrinogen conversion 
to fibrin and cross-linking of fibrin chains, therefore causing 
resistance to clot lysis and propensity to recurrent coronary 
thrombosis which can be at least partially inhibited by anti-
thrombin agents. However, extensive plasmin activity also 
induces proteolysis of fibrinogen and coagulation factors 
which inhibit thrombosis by interfering with fibrin polymeri-
zation and platelet aggregation thus exerting an anticoagu-
lant effect. The balance between prothrombotic and antico-
agulant effects of thrombolytics is different for fibrin-
specific as compared with non fibrin-specific agents being 
the extent of fibrinogen degradation more pronounced with  
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the latter than with the former [3]. Accordingly, a 24 to 48-
hour course of intravenous unfractionated heparin (UFH) is 
currently recommended (Class I recommendation) as an ad-
junct to thrombolysis with fibrin-specific agents (alteplase, 
reteplase, or tenecteplase), whereas such recommendation is 
less compelling (Class IIb recommendation) when strep-
tokinase is given instead [3, 4].  
  UFH consists of an heterogeneous mixture of poly-
saccharide chains with a molecular weight of 3,000 to 30,000 
daltons,andactsas an anticoagulant by activating anti-throm-
bin. This activation resides on a specific pentasaccharide se-
quence which has high affinity for antithrombin and is ran-
domly dispersed within the heparin molecule. Whereas UFH 
chains of any length containing this unique sequence can 
bind to antithrombin and promote inactivation of factor Xa, 
the formation of the ternary complex of UFH-anti-thrombin-
thrombin necessary to enhance inhibition of thrombin (factor 
IIa) can occur only with UFH molecules with > 18 saccha-
ride units. Since UFH is primarily composed of chains with 
> 18 units, the anti-Xa:anti-IIa potency is approximately 1:1. 
On the contrary, low-molecular-weight heparins (LMWH), 
which are obtained by chemical or enzymatic depolymeriza-
tion of UFH, are enriched of shorter chains, with a mean mo-
lecular weight of 5,000 daltons, and preferentially inhibit 
factor Xa. Such action, obtained again by the formation of a 
LMWH-antitrombin complex, is not chain-length dependent, 64 Current Cardiology Reviews, 2008, Vol. 4, No. 1 Andrea Rubboli
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as it is for factor IIa. As a consequence, LMWH act more 
upstream than UFH in the coagulation cascade, and are 
therefore more efficient. In addition, LMWH as compared to 
UFH bind significantly less to plasma proteins, are less neu-
tralized by platelet factor 4, and are associated with less side 
effects, such as heparin-induced thrombocytopenia and os-
teoporosis. Finally, LMWH have increased bioavailability 
and dose-dependant clearance, which make the anticoagulant 
response more predictable and routine laboratory monitoring 
unnecessary. 
  Because of these potential advantages, LMWH have been 
evaluated in recent years as an adjunct to thrombolysis in 
STEMI, and are currently recommended as an acceptable 
alternative to UFH (Class IIb recommendation), provided 
that patients are less than 75 years of age and significant re-
nal dysfunction (serum creatinine > 2.5 mg/dl in men or 2.0 
mg/dl in women) is absent [3, 4]. 
  In this review, the studies of LMWH in combination with 
fibrinolytics which are at the basis of current recommen-
dations are examined. Also, newer evidence on this issue, 
which has recently become available, is reviewed. 
CLINICAL TRIALS (TABLE 1) 
The clinical studies of LMWH with thrombolytic treat-
ment in STEMI highly differ in design, compound evaluated, 
thrombolytic used, doses and duration of treatments, and 
endpoints. Because of these reasons, as well as of the differ-
ent pharmacokinetic and pharmacologic properties, the vari-
ous LMWH are reviewed separately, and a cumulative 
analysis is subsequently attempted.  
Dalteparin 
  In the FRAMI study [5], 776 patients with anterior 
STEMI and receiving streptokinase, were randomized to dal-
teparin or placebo. The primary endpoint was the composite 
incidence of left ventricular thrombosis and arterial embo-
lism. Upon evaluation of only the patients who continued 
treatment (64% of dalteparin and 70% of placebo patients), 
the occurrence of primary endpoint was significantly reduced 
by dalteparin, with no significant effect on the reinfarction 
and mortality rates, but with a significantly higher risk of 
both major and minor bleedings. 
  The BIOMACS study [6] evaluated 101 patients treated 
with streptokinase, who were randomized to dalteparin or 
placebo. The primary outcome, as represented by TIMI 3 
flow grade at 20-28 hours, did not significantly differ be-
tween the two groups, although TIMI 0-1 flow grade, and its 
combination with intraluminal thrombus, were significantly 
less frequent in the dalteparin group. As regards clinical 
events, a significantly less incidence at both 24 hours (ex-
cluding the initial 6 h when unstable coronary blood flow is 
common) and 7 days was observed with dalteparin, in the 
absence of differences in the major/minor bleeding rate. 
  The ASSENT PLUS trial [7] compared dalteparin with 
UFH as an adjunct to alteplase in 1639 patients, aiming at 
evaluatingTIMI3flowgrade at 4-7 days (primary end-point). 
Achievement of TIMI 3 flow grade, which was evaluated in 
86% of patients, was similar in both groups, whereas rein-
farction rate at 7 days was significantly less with dalteparin. 
Such difference however, was not sustained at 30 days. Fi-
nally, no differences in bleedings were reported. 
Reviparin 
  In the CREATE trial [8], 15,570 patients were rando-
mized to reviparin or placebo as an adjunct to thrombolysis. 
The two composites primary end-points of death, reinfa-
rction or stroke and previous plus recurrent ischemia with 
electrocardiogram changes were significantly reduced at 7 
days with reviparin. These benefits were persistent at 30 
days, when significant reductions in mortality and reinfa-
rction rates were also present. No significant differences 
were observed in stroke rates. At 7 days, an increase in life-
threatening and major bleeding was observed with reviparin, 
although such a small absolute increment (1 event/1000 
treated patients) should be acknowledged, especially when 
the reduction of both primary end-point (18 fewer events/ 
1000 treated patients) and mortality (15 fewer events/1000 
treated patients) are considered.
Enoxaparin 
 Glick  et al. [9], randomized 103 patients to either subcu-
taneous enoxaparin or placebo for the next 25 days, follow-
ing treatment with aspirin, streptokinase and UFH for the 
first 5 days. The primary end-point of combined occurrence 
of unstable angina, reinfarction and death at 6 months was 
significantly reduced in the enoxaparin group, mainly as a 
consequence of the decreased reinfarction rate, since the oc-
currence of unstable angina and death were comparable. 
  In the HART-II study [10], 400 patients receiving aspirin 
and accelerated rt-PA, were randomized to enoxaparin or 
UFH. The primary end-point was the IRA patency at 90’ and 
5-7 days, while the secondary end-point was the occurrence 
of major bleedings. At 90’ TIMI 2-3 and TIMI 3 flow grades 
in the infarct-related artery (IRA) did not significantly differ 
in the two groups. Also, the reocclusion rate at 5-7 days was 
comparable, although a clear trend favoring enoxaparin was 
evident. Major bleedings occurred with similar frequency in 
both groups. 
  In the ASSENT-3 trial [11], 6095 patients treated with 
aspirin were randomized to: 1) full-dose tenecteplase and 
enoxaparin; 2) half-dose tenecteplase with weight-adjusted 
low-dose UFH and abciximab; 3) full-dose tenecteplase and 
weight-adjusted UFH. Primary end-points were the compo-
sites of 30-day mortality, in-hospital reinfarction/ refractory 
ischemia (efficacy end-point), and the above end-points plus 
in-hospital intracranial hemorrhage/major bleedings (effi-
cacy plus safety end-point). In association with full-dose 
tenecteplase, enoxaparin was significantly more effective on 
the primary efficacy end-point, as well as on the primary ef-
ficacy plus safety end-point. The association of abciximab 
and UFH influenced both efficacy and efficacy plus safety 
end-points comparably to enoxaparin and superiorly to UFH. 
Enoxaparin significantly reduced in-hospital reinfarction and 
refractoryischemia, along with in-hospital death/reinfarction. 
Major hemorrhagic complications were not significantly dif-
ferent with enoxaparin as compared to UFH. 
  The ENTIRE-TIMI 23 study [12] was carried out on 483 
patients to determine the effect on the 60’ patency rate of the 
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ated in the ASSENT-3 trial [11] plus an additional one with 
half-dose tenecteplase associated with enoxaparin and ab-
ciximab. The 4 regimens were similarly effective on the pri-
mary end-point of IRA TIMI 3 flow grade at 60’, which was 
about 50% in all groups. When pooling the results of the dif-
ferent groups according to heparin treatment, the IRA TIMI 
3 and TIMI 2-3 flow grade rates were comparable. A favor-
able trend towards a complete ST-segment resolution at 180’ 
was observed in enoxaparin groups. Evaluation at 30 days by 
a blinded Clinical Events Committee of the clinical efficacy 
end-points showed significantly less death/reinfarction with 
enoxaparin, when administered with full-dose tenecteplase. 
This was mainly due to the reduction in reinfarction, which 
could also be observed when pooling all enoxaparin vs all 
UFH patients. No effect of the two heparin regimens was ap-
parent with the combination treatments including abciximab. 
Through 30 days, the occurrence of major bleedings was 
similar in both groups treated with full-dose tenecteplase, 
regardless of the heparin regimen used. When abiciximab 
was added, a trend towards a higher bleeding rate was ob-
served with enoxaparin as compared to UFH. Such a trend 
was also apparent for enoxaparin when pooling patients with 
respect to the heparin regimen adopted.  
 Baird  et al. [13] enrolled 300 patients receiving strepto-
kinase or anistreplase (but not aspirin, which was given only 
at the end of the investigated treatment), who were random-
ised to either enoxaparin or UFH. The primary end-point was 
the occurrence at 90 days of the composite of death, reinfarc-
tion or rehospitalization due to unstable angina. Enoxaparin 
was significantly more effective than UFH, leading to a 30% 
relative risk reduction of death, reinfarction or recurrent an-
gina. This effect was obtained through a consensual reduc-
tion of any single component of the composite end-point. 
Significant bleeding occurred comparably in the two treat-
ment groups. 
  In the AMI-SK study [14], 496 patients treated with aspi-
rin and streptokinase were randomized to enoxaparin or pla-
cebo. The primary end-point was the IRA patency rate at 5-
10 days, while secondary end-points were ST-segment reso-
lution at 90’ and 180’ and occurrence of combined death, 
reinfarction, recurrent angina and major bleedings at 30 
days. Enoxaparin was significantly more effective on the 
primary end-point and complete ST-segment resolution both 
at 90’ and 180’. Clinical events at 30 days were also signi-
ficantly reduced in the enoxaparin group, mainly as a conse-
quence of the reduction of reinfarction. Major hemorrhages 
were more frequent with enoxaparin, although this difference 
was not statistically significant. 
  In the ASSENT-3 PLUS study [15], 1639 patients were 
randomly assigned in a pre-hospital setting to treatment with 
tenecteplase and either enoxaparin or weight-adjusted UFH. 
The primary end points were: composite of 30-day mortality 
or in-hospital reinfarction/refractory ischemia (efficacy end 
point) and composite of the previous plus in-hospital intra-
cranial hemorrhage/major bleedings (efficacy plus safety end 
point). Enoxaparin was comparable to UFH on both the pri-
mary efficacy and efficacy plus safety end points. Analysis 
of the individual components of the end points showed a re-
duction in in-hospital reinfarction and refractory ischemia 
rates, but an increase in total stroke and intracranial hemor-
rhage with enoxaparin. The increase in intracranial hemor-
rhage however, was seen exclusively in patients over 75 
years of age. 
  The ASENOX study [16], included 633 consecutive pa-
tients who received aspirin and were randomly assigned to 
either: 1) accelerated streptokinase plus enoxaparin (ASKE-
NOX group = 165 patients); 2) accelerated streptokinase plus 
UFH (ASKUFH group = 264 patients) or 3) regular strepto-
kinase plus UFH (SSKUFH group = 204 patients). When 
considering the 429 patients in the ASKENOX and 
ASKUFH groups, the coronary reperfusion rate (defined as 
cessation of chest pain during the first 180’ of thrombolysis, 
rapid reduction of ST-segment elevation by more than 50% 
of the initial value within the first 180’ and rapid increase in 
plasma CK and CK-MB with a peak in the first 12 h) was 
comparable. Also 30-day mortality was comparable in both 
groups and neither significant difference in the incidence of 
major or minor hemorrhage was observed. 
CUMULATIVE ANALYSIS OF CLINICAL TRIALS 
  An overview of the clinical studies of LMWH as an ad-
junct to thrombolysis for STEMI has been recently published 
[17]. Although highly different in design, thrombolytic agent 
and LMWH used, these trials generally show a favourable 
effect of dalteparin, reviparin and enoxaparin on the clinical 
efficacy end-points, not only in comparison to placebo [5, 6, 
8, 9, 14], but also to UFH [15, 11-13, 15, 16] (Table 1). 
Whereas mortality is not generally influenced by the treat-
ment with LMWH (with the only exception of the CREATE 
study [8], where death rate was significantly reduced at both 
7 and 30 days with reviparin as compared to placebo), the 
occurrence of reinfarction and recurrent ischemia/angina is 
in general reduced, as compared to both placebo [6, 8, 9, 14] 
and UFH [11, 12, 15] (Table 1). The different definitions of 
recurrent ischemia/angina and reinfarction, as well as the dif-
ferent thrombolytic (with either fibrin-specific or non fibrin-
specific agents) and both LMWH and UFH regimens, may 
well explain the lack of a significant positive effect which 
was nonetheless observed in some trials [5-7, 13, 14, 16]. 
Also, the known differences in the pharmacokinetic proper-
ties and anticoagulation profile might, at least in part, explain 
the different results obtained with different LMWH. For ex-
ample, enoxaparin has about twice longer plasma half-life 
and twice higher anti factor Xa activity than dalteparin [18]. 
In addition, enoxaparin, but not dalteparin, has been shown 
to reduce the levels of von Willebrand factor, which in turn, 
are associated to a poorer prognosis at 30 days in patients 
with non-ST elevation acute coronary syndromes [19]. Rela-
tive to the angiographic efficacy end-points, no significant 
differences were observed with LMWH compared to UFH 
on the acute (60-90’ to 24 h) patency rate of the IRA [6,  
10, 12] (Table 1). On the other hand, late patency (4 to 10 
days) and/or reocclusion rates of the IRA, were in general, 
favourably influenced by LMWH, although statistical   
significance was seldom reached [10, 14, 15] (Table 1). Fi-
nally, the safety profile of LMWH is characterized in   
general, by an increased occurrence of both minor and   
major bleedings compared to placebo [5, 8, 14] and substan-
tially unchanged compared to UFH [7, 10-13], with only ex-
ception of the ASSENT-3 Plus study [15] where, in a pre-
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Table 1.  Clinical Trials with Dalteparin, Enoxaparin and Reviparin 
Study N°  Pts   Treatment    Treatment 
Duration 
End points  Results (%) 
Active vs Control
Active Control      
Dalteparin
FRAMI [4]  776    SK + ASA +    9 days  1°: LV thrombus, arterial 
embolism at 9 days 
14–22* 
    D 150 IU/kg sc x 2    placebo    2°: death/myocardial rein-
farction at 3 months 
BIOMACS II 
[5] 
101    SK + ASA +    20-28 h  1°: TIMI grade 3 flow in 
IRA at 24 hours 
2–2/6 - 6 
    D 100 IU/Kg sc +    placebo +    2°: ischemic ECG episodes 
at 1/21 days 
68-51 
    only D 120 IU/kg sc 12 h later          
ASSENT [6] 
PLUS 
439 rt-PA + ASA 
+
4-7 days D/48 
h UFH 
1°: in-H TIMI grade 3 flow 
in IRA 
69-63 
D 120 IU/kg 
dose iv + 
UFH 
4000/5000 
IU iv + 
  2°: death at 7/30 days  2.3-3.8/4.1–5.2 
D 120 IU/kg 
dose sc + 
UFH 
800/1000 
IU/h iv 
2°: myocardial reinfarction 
at 7/30 days 
1.4–5.4*/6.5-7 
    D 120 IU/kg sc x 2        2°: major bleeding at 30 
days 
3.7–4.6 
Reviparin              
CREATE [7]  15570    Throm-
bolytic + 
ASA + 
 7  days  1°: death, reinfarction, 
stroke at 7 days 
9.6–11* 
<50Kg R 3436IU 
sc x 2 
 placebo    1°: previous + recurrent 
ischemia at 7 days 
11.1–12.6* 
50-75Kg R 5153IU 
sc x 2 
 placebo    2°: death, reinfarction, 
stroke at 30 days 
11.8–13.6* 
>75Kg R 6871IU 
sc x 2 
 placebo    2°: previous + recurrent 
ischemia at 30 days 
13.8–15.6* 
            2°: major bleeding at 7 days  0.9–0.4* 
Enoxaparin              
Glick et al. [8]  103    SK + ASA + 
UFH iv for 5 
days + 
 25  days  1°: death, reinfarction, an-
gina at 6 months 
14–43* 
    E 40mg/die sc    placebo       
HART-II [9]  400    rt-PA + ASA 
+
 3  days  1°: TIMI 2-3 grade flow in 
IRA at 90’ 
80-75 
    E 30mg iv +    UFH 5.000 IU 
iv + 
  2°: in-H major bleeding  5.6-5 
    E 1mg/kg sc x 2    15 IU/kg/h 
iv 
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(Table 1. Contd….) 
Study N°  Pts   Treatment    Treatment 
Duration 
End points  Results (%) 
Active vs Control
Active Control      
ASSENT-3 
[10] 
6095 • full-dose TNK + 
ASA +  
full-dose 
TNK + ASA 
+
7 days E/48 h 
UFH 
1°: death at 30 days, in-H 
reinfarction and angina 
11–15* 
E 30mg iv + 
1mg/Kg sc x 2 
UFH 60 
IU/kg iv +12 
IU/kg/h iv 
1°: previous + in-H major 
bleeding 
14–17* 
       • half-dose 
TNK + ASA 
+
2°: in-H reinfarc-
tion/refractory ischemia 
3–4*/5–7* 
       UFH 40 
IU/kg +7 
IU/kg iv + 
abciximab 
12 h 
  2°: in-H major bleeding  3–2 
ENTIRE [11]  483    as in AS-
SENT–3 trial 
+
 8 days E/
36 h UFH 
1°: TIMI grade 3 flow at 60’  50-51 
 TIMI 23     half-dose TNK + E 
1 mg/kg sc x 2 + 
abciximab 12 h 
     1°: major bleeding at 30 
days 
2–2
           2°: death, reinfarction at 30 
days 
4–16* 
Baird et al.
[12] 
300 Throm-
bolytic + 
 4  day  1°: death, reinfarction, an-
gina at 90 days 
26–36* 
    E 40mg iv +    UFH 5.000 
IU iv + 
  2°: major bleeding at 4 days  3-4 
    E 40mg sc x 3    UFH 30.000 
IU/24 h 
    
AMI-SK [13]  496  +  SK + ASA    3-8 days  1°: TIMI 3 grade flow in 
IRA at 5-10 days 
70–58* 
    E 30 mg iv +    placebo    2°: death, reinfarction, an-
gina at 30 days 
13–21* 
    E 1 mg/kg sc x 2        2°: major bleeding at 30 
days 
5-3 
ASSENT-3 
[14] 
1639 TNK + ASA 
+
 7 days E/48 
h UFH 
1°: death at 30 days, in-H 
reinfarction and angina 
14-17 
 PLUS     E 30mg iv +    UFH 60 
IU/kg +12 
IU/kg/h iv 
1°: previous + in-H major 
bleeding 
18-20 
    E 1 mg/kg sc x 2        2°: stroke + intracranial 
hemorrhage 
2-1 
ASENOX [15]  429 ASK + ASA 
+
 7 days E/
72 h UFH 
1°: Reperfusion rate (nonin-
vasive criteria) 
77.6–73.5 
E 40 mg iv + 1 
mg/kg sc x 2 
UFH 1000 
IU/h 
  2°: mortality at 30 days  6.1–6.8 
1°: primary end-point; 2°: secondary end-point; D: dalteparin; E: enoxaparin; R: reviparin; rt-PA: alteplase; SK: streptokinase; ASK: accelerate regimen of streptokinase in 20 min; 
TNK: tenecteplase; ASA: aspirin; LMWH: low molecular weight heparin; UFH: unfractionated heparin; IRA: infarct-related artery; LV: left ventricle; sc: subcutaneously; iv: intrave-
nously; H: hospital. * p < 0.05. 68 Current Cardiology Reviews, 2008, Vol. 4, No. 1 Andrea Rubboli
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associated, albeit in patients older than 75 years only, with a 
twice higher occurrence of intracranial hemorrhage (Table 
1).  
  The randomized clinical trials on LMWH as compared to 
either placebo or UFH as adjuncts to thrombolysis in STEMI 
have also been an object of a recent meta-analysis [20]. In 
the 4 trials where LMWH were compared to placebo, about 
17,000 patients were evaluated, only non fibrin-specific 
thrombolytics were used, and either enoxaparin, dalteparin or 
reviparin were evaluated [5, 6, 8, 14]. Treatment with 
LMWH reduced the occurrence of reinfarction and death by 
about one quarter and 10% during both hospitalization/at 7 
days and at 1 month. Fig. (1) [20]. A nonsignificant excess 
of (hemorrhagic) stroke was observed with LMWH both dur-
ing hospitalization/at 7 days (OR 1.19; 95% CI 0.84-1.70) 
and at 30 days (OR 1.19; 95% CI 0.86-1.65), whereas the 
increase of in-hospital/at 7 days increase of both major (OR 
2.70; 95% CI 1.83.3.99) and minor (OR 3.24; 95% CI 2.12-
4.91) bleeds was significant [20]. LMWH were compared to 
UFH in 6 trials, where about 7,000 patients were enrolled, 
both fibrin- and non fibrin-specific thrombolytics were used, 
and enoxaparin and dalteparin evaluated [7, 10-13, 15]. Dur-
ing both hospitalization/at 7 days and 30 days, the reinfarc-
tion rate was significantly reduced by LMWH, whereas the 
decrease in death was not significant. Fig. (2) [20]. There 
was also a nonsignificant increase of stroke (OR 1.38; 95% 
CI 0.95-2.01) and intracranial hemorrhage (OR 1.18; 95% CI 
0.74-1.87) during hospitalization/at 7 days, which persisted 
at 30 days for stroke (OR 1.19; 95% CI 0.79-1.91) [19]. In-
hospital/at 7 days bleeding rate was increased with LMWH, 
although statistical significance was reached only for minor 
(OR 1.26; 95% CI 1.12-1.43) and not for major (OR 1.30; 
95% CI 0.98-1.72) events [20].  
  Therefore, according to the cumulative analysis of cur-
rently available trials, LMWH as an adjunct to thrombolysis 
in STEMI appear more effective than placebo and at least as 
effective as (if not superior to) UFH. The higher efficacy of 
LMWH as compared to UFH observed in some studies on 
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the occurrence of reinfarction, may in fact not be real, since 
it may derive from different durations (longer with LMWH) 
of heparin treatments [7, 11, 12, 15]. Indeed, no differences 
on the occurrence of reinfarction and recurrent angina were 
observed when LMWH and UFH were given for the same 
time period [13]. Also, it should be taken into account that 
UFH may have been underdosed, as in ASSENT-3 [11] and 
ASSENT-3 Plus [15] trials, where the target aPTTs resulted 
below-range in about half of the patients, therefore possibly 
resulting in lower antithrombotic efficacy of UFH.  
  To summarize, clinical evidence from the trials reviewed 
above supports the use of LMWH (essentially enoxaparin) as 
a valid alternative (if not the treatment to be preferred) to 
UFH as an adjunct to thrombolysis young (< 75 years old) 
STEMI patients without renal dysfunction. Whereas suffi-
cient evidence does not exist to make this recommendation 
for dalteparin, further and stronger data in favour of enoxa-
parin have been recently obtained for the ExTRACT-TIMI 
25 trial [21] 
Fig. (2). Efficacy of low-molecular-weight heparins (LMWH) as compared to unfractionated heparin (UFH) in 6 randomized clinical trials 
(from reference [19]). * Outcome for Baird et al. [12] is at 90 days. 70 Current Cardiology Reviews, 2008, Vol. 4, No. 1 Andrea Rubboli
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THE ExTRACT-TIMI 25 TRIAL 
  In this multi-center, double-blind, randomized trial, over 
20.000 patients receiving either a fibrin- or non fibrin-
specific thrombolytic and aspirin, were randomized to intra-
venous bolus of UFH 60 IU/kg followed by infusion of 12 
IU/kg/h for 48 hours, or enoxaparin 30 mg as an intra-venous 
bolus followed by 1 mg/kg twice daily subcutaneously for up 
to 8 days [21]. In patients at least 75 years of age the intra-
venous bolus was eliminated and the subcutaneous dose re-
duced to 0.75 mg/kg every 12 hours, whereas in patients 
with an estimated creatinine clearance of less than 30 ml/min 
the dose was modified to 1 mg/kg every 24 hours [21]. The 
primary end-point was the composite of death or reinfarction 
at 30 days, whereas secondary end points were the composite 
of death and reinfarction/recurrent ischemia and the compos-
ite of death, recurrent reinfarction and disabling stroke at 30 
days. Enoxaparin was significantly more effective than UFH 
on both in-hospital (7% vs 9%; p<0.001) and 30-day (10% 
vs 12%; p<0.001) primary end point. Fig. (3) and Fig. (4). In 
both cases, this result was mainly driven by the significant 
decrease in reinfarction, since mortality was not substantially 
affected. Fig. (3) and Fig. (4). At 30 days, major bleedings 
were significantly more frequent with enoxaparin (in spite of 
the dose-adjustments according to age and renal function) 
(2.1% vs 1.4%; p<0.001), although the occurrence of intrac-
ranial hemorrhage was comparable (0.8% vs 0.7%) Fig. (4). 
However, the net clinical benefit at 30 days, defined as the 
combined occurrence of death, reinfarction and either nonfa-
tal disabling stroke, major bleeding or intracranial hemor-
rhage, was significantly higher with enoxaparin, which was 
associated with a significant 14 to 18% relative risk redu-
ction of these events compared to UFH. Because of its de-
sign and size, the ExTRACT-TIMI 25 study [21] should be 
considered conclusive about the superior efficacy of enoxa-
parin in comparison to UFH for the treatment of patients re-
ceiving thrombolysis for STEMI. Again however, it cannot 
be determined whether this result is to be ascribed to a true 
superior antithrombotic effect of enoxaparin or instead to the 
longer duration of treatment (7 days vs 48 hours). Also, the 
higher occurrence of major bleedings may also well ascribed 
to the longer duration of treatment, rather than to a superior 
dangerousnessofenoxaparin. Since however, the most dread-
ful and disabling hemorrhagic complication, represented by 
intracranial bleeding, did not significantly differ in the two 
groups, the safety profile of enoxaparin should be considered 
satisfactory.  
CONCLUSIONS 
  The administration of LMWH as an adjunct to thrombo-
lysis with either fibrin- and non fibrin-specific agents in 
Fig. (3). Efficacy and safety outcomes at 8 days in the ExTRACT-TIMI 25 study [20]. UFH = unfractionated heparin; ICH = intracranial 
hemorrhage; RR = relative risk; NS = nonsignificant. 
Fig. (4). Efficacy and safety outcomes at 30 days in the ExTRACT-TIMI 25 study [20]. UFH = unfractionated heparin; ICH = intracranial 
hemorrhage; RR = relative risk; NS = nonsignificant. Efficacy and Safety of Low-Molecular-Weight Heparins  Current Cardiology Reviews, 2008, Vol. 4, No. 1    71
STEMI patients appears at least as effective as safe as UFH. 
Because of the easiness of subcutaneous administration and 
the lack of need for aPTT monitoring they should be strongly 
considered in this clinical setting, since prolonged anti-
thrombotic treatment is possible, without hampering early 
mobilization and rehabilitation of patients. Because enoxa-
parin has been the most extensively studied LMWH and has 
most consistently shown a superiority to both placebo and 
UFH on both in-hospital and 30-day occurrence of reinfarc-
tion/recurrent ischemia, and angiographic end-points, such as 
patency and reocclusion rates of the IRA, it should be con-
sidered the compound of choice. Provided that patients are 
aged less than 75 years and significant renal dysfunction is 
absent, enoxaparin should be administered as a 30-mg intra-
venous bolus immediately prior to thrombolytic administra-
tion followed by 1 mg/kg subcutaneously twice daily for 
about 1 week. Before definitively replacing UFH however, 
some important, and yet unresolved issues, such as the use in 
elderly patients, and in conjunction with glycoprotein IIb/IIIa 
inhibitors and percutaneous coronary interventions, need to 
be addressed.  
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